{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:59:03Z","timestamp":1792616343969,"version":"4.5.0"},"reference-count":23,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T00:00:00Z","timestamp":1356480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Ivermectin is a broad\u2010spectrum parasiticide in widespread systemic use, including as an off\u2010label treatment for head lice infestation. The potential of the topical use of ivermectin as a treatment for head lice infestation was suggested by an <jats:italic>in vitro<\/jats:italic> report of a novel lotion formulation.<\/jats:p><jats:p><jats:bold>Objectives\u2002<\/jats:bold> This study investigated the relative effectiveness of three ivermectin lotion concentrations (0.15, 0.25, and 0.5%) compared with vehicle placebo in eliminating head lice infestation.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold> In this randomized, blinded study, 78 head lice\u2010infested subjects, aged 2\u201362\u2003years, received a single, 10\u2010minute application of product on day 1. Evaluations were completed at two and six hours post\u2010application, and on days 2, 8 (\u00b11), and 15 (+2). Safety was assessed according to the evaluations of trained observers and adverse event (AE) reports. Efficacy was assessed according to scalp and hair examinations.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Compared with placebo, all ivermectin concentrations resulted in the statistically significant (<jats:italic>P\u2003<\/jats:italic>\u2264\u20030.003) eradication of head lice through to day 15, with the highest level of eradication (73.7%) in subjects who received the 0.5% concentration. The severity of pruritus decreased from baseline in all treatment groups, including the placebo group, from six hours post\u2010treatment to day 15, with the greatest reduction in the 0.5% concentration group. No ocular irritation was observed. All three ivermectin treatment strengths and vehicle were well tolerated.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> A single application of a 0.5% concentration of this ivermectin lotion formulation shows promise as a safe and effective treatment for head lice infestation and the associated signs of pruritus.<\/jats:p>","DOI":"10.1111\/j.1365-4632.2012.05629.x","type":"journal-article","created":{"date-parts":[[2012,12,26]],"date-time":"2012-12-26T14:10:55Z","timestamp":1356531055000},"page":"106-112","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Assessment of the safety and efficacy of three concentrations of topical ivermectin lotion as a treatment for head lice infestation"],"prefix":"10.1111","volume":"52","author":[{"given":"Terri L.","family":"Meinking","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamara","family":"Mertz\u2010Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margie","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,26]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"1535","volume-title":"Pediatric Dermatology","author":"Meinking TL","year":"2010"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-1308"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1177\/10598405070230050701"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2007.00460.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.01059.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.4065\/79.5.661"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1179\/136485908X337418"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000317"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1011983107"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.33.20187"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199507063330105"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/499279"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.041"},{"key":"e_1_2_6_15_2","first-page":"253","article-title":"Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis)","volume":"45","author":"Glaziou P","year":"1994","journal-title":"Trop Med Parasitol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905471"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2010.01317.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1995.53.652"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1603\/0022-2585(2008)45[75:ANIFTK]2.0.CO;2"},{"key":"e_1_2_6_20_2","first-page":"115","article-title":"In vitro confirmation of the efficacy of a novel ivermectin lotion formulation to treat Pediculus humanus capitis. Fourth International Conference on Phthiraptera","volume":"34","author":"Meinking TL","year":"2010","journal-title":"Turkiye Parazitol Derg"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3762"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1603\/ME11051"},{"key":"e_1_2_6_23_2","unstructured":"HazanL CorradoM.Pharmacokinetics safety and effectiveness of a 0.5% ivermectin lotion cream in head lice\u2010infested children. [Abstract #22.] Presented at the Society for Pediatric Dermatology July 15\u201318 2010 Portland OR."},{"key":"e_1_2_6_24_2","unstructured":"Food and Drug Administration.Stromectol\u00ae(ivermectin) prescribing information.http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/050742s026lbl.pdf. (Accessed February 1 2012.)"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-4632.2012.05629.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-4632.2012.05629.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T06:13:19Z","timestamp":1697350399000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-4632.2012.05629.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,26]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1111\/j.1365-4632.2012.05629.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-4632.2012.05629.x","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,26]]},"assertion":[{"value":"2012-12-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}